myron s. cohen, md associate vice chancellor director, institute for global health
DESCRIPTION
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina. Essential New Technologies. HIV Incidence -An algorithm (HPTN 043) -CDC -IgG3 Point of Care Viral Load - Alere -Others. EXPOSED. UNEXPOSED. EXPOSED. - PowerPoint PPT PresentationTRANSCRIPT
Myron S. Cohen, MDAssociate Vice Chancellor
Director, Institute for Global Health The University of North Carolina
Essential New Technologies• HIV Incidence -An algorithm (HPTN 043) -CDC• -IgG3• Point of Care Viral Load -Alere -Others
Four HIV Prevention Opportunities
YEARS
Treatment Of HIVReduced Infectivity
INFECTED
YEARS
UNEXPOSED
Behavioral,Structural
Circumcision
CondomsSTIs
Cohen et al, JCI, 2008Cohen IAS 2008
HOURS
VaccinesART PrEP
Microbicides
EXPOSED (precoital/coital)
72h
VaccinesART PEP
EXPOSED (postcoital)
HPTN 052: What’s Next
The HPTN 052 Cohort July 2012
1682/1763 index cases (96% retention) 1502 discordant couples (85% retention) DURABILITY OF PREVENTION? DELAYED CLINICAL EVENTS?
The “Test and Treat” MovementGranich et al. Current Opinion in HIV, 2011
More than 50 studies described!!• US HPTN 065 Linkage in NYC, DC• ANRS/Africa Center-South Africa• THE PEPFAR Combination Prevention Trials:
– CDC- BOTSWANA– NIH HPTN 071 -South Africa, Zambia – USAID JHU-Tanzania
HPTN 071 Intervention Package Community HIV Care Providers (CHiPs team):
• Counselling, condom provision, syndromic STI Rx• Referral of pregnant women for ANC/PMTCT services• Universal voluntary HIV testing house-to-house • HIV-uninfected men offered circumcision • HIV-infected persons
− Arm A: Immediate ART (analogous to HPTN 052)− Arm B: “Enhanced” Standard of Care (CD4<350)− Arm C: Standard of Care (CD4<350)
10-510-4
10-3
10-2
10-10
101
102
103
104105
106
107
108
Transmission
Viru
s Con
cent
ratio
n in
Ext
race
llula
r Fl
uid
or
Plas
ma
(Cop
ies/
ml)
Time Post Exposure (days)
0 5 10 15 20 30 3525 40 45 50 55 60 65 70
Reservoir Vi
rus
disse
mina
tion
Transit
eclipse?
T0
Acute Phase ReactantsDays -5 to-7
Immune ComplexesDay 9
Onset cytokinesapoptosis, Day 7 Free Antibody, Day 13
CD8 T CellResponses
CTL Escape
AutologousNeutralizing Antibody
AutologousNeutralizing
Antibody Escape
Acute HIV-1 Infection: A Challenge Cohen et al, NEJM, 2011
The Next PrEP/Microbicides
• Do the results increase adherence: iPREX OLE?• Can Truvada schedule change (HPTN 066,067)• Can Maraviroc be used as PrEP (HPTN 069)• Other oral agents? • Other topical agents• The Ring• Can injectable agents be developed as PrEP
Can We Cure AIDS?
To be published 26 July 2012Available on-line 1 PM 25 July 2012